医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China

2020年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: “Meiji”) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.

Daikichiro Kobayashi, President and Representative Director said “First of all, we extend our sincerest condolences to the victims and their families. For about 30 years, we have been operating its business in Guangdong and Shandong, and we greatly appreciate the customers and partners all over in China. We would like to give our support to everyone there and hope our donation helps.”

We sincerely pray for early recovery of Novel coronavirus associated pneumonia patients and the end of virus infection in China.

Details of the donation
- Amount of contribution: RMB 1 million (approximately JPY 16 million)
- Donated to: Red Cross Society of China

View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005336/en/

CONTACT

Beijing Office: (010)65388196

Zhao Chengguo

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates